Antitumor effect of transcatheter arterial embolization in combination with sorafenib in a rabbit VX2 liver tumor model

Research Project

Project/Area Number	25861084
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Radiation science
Research Institution	Shiga University of Medical Science
Principal Investigator	TOMOZAWA Yuki 滋賀医科大学, 医学部, 助教 (90585689)
Project Period (FY)	2013-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000) Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	ソラフェニブ / 肝動脈塞栓 / 肝動脈塞栓術
Outline of Final Research Achievements	Using a VX2 liver tumor model, we investigated antitumor effect of the combination of TACE with sorafenib and suitable timing parameters when using sorafenib to enhance the anti-tumor effects of TAE. In conclusion, we suggest that a combination of sorafenib with TAE is a more effective treatment than sorafenib or TACE alone and the ideal time of TAE is prior to or early after commencement of administration Sorafenib.

Report

(3 results)